Vanguard Personalized Indexing Management
PTGX icon

Vanguard Personalized Indexing Management’s Protagonist Therapeutics PTGX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$733K Buy
5,978
+306
+5% +$32K 0.01% 1170
2026
Q1 		$598K Buy
5,672
+2,099
+59% +$186K 0.01% 1208
2025
Q4 		$312K Buy
3,573
+275
+8% +$22.5K ﹤0.01% 1504
2025
Q3 		$219K Buy
+3,298
New +$187K ﹤0.01% 1651

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Personalized Indexing Management's PTGX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Protagonist Therapeutics (PTGX) stake by 5.4% in Q2 2026, buying an estimated $32K and bringing the position to 5,978 shares worth $733K. The position accounts for 0.01% of the portfolio, ranked #1170.

Vanguard Personalized Indexing Management first reported a position in PTGX in Q3 2025 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 5,978 shares of Protagonist Therapeutics worth $733K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 306 Protagonist Therapeutics shares in Q2 2026, an estimated $32K.
  • Protagonist Therapeutics made up 0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1170 holding.
  • Vanguard Personalized Indexing Management first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.